(MedPage Today) — TORONTO — Biomarkers pointing to increased risk for Alzheimer’s disease were markedly reduced with the investigational cholesteryl ester transfer protein (CETP) inhibitor obicetrapib relative to placebo in a large phase III…
Source link : https://www.medpagetoday.com/meetingcoverage/aaic/116765
Author :
Publish date : 2025-07-31 18:51:00
Copyright for syndicated content belongs to the linked Source.
